ES2658224T3 - Anticuerpos humanizados contra receptores de tipo Toll 2 y sus usos - Google Patents
Anticuerpos humanizados contra receptores de tipo Toll 2 y sus usos Download PDFInfo
- Publication number
- ES2658224T3 ES2658224T3 ES14158199.1T ES14158199T ES2658224T3 ES 2658224 T3 ES2658224 T3 ES 2658224T3 ES 14158199 T ES14158199 T ES 14158199T ES 2658224 T3 ES2658224 T3 ES 2658224T3
- Authority
- ES
- Spain
- Prior art keywords
- receptors
- antibodies against
- humanized antibodies
- epitope
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 abstract 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 abstract 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 abstract 1
- 108010073807 IgG Receptors Proteins 0.000 abstract 1
- 102000009490 IgG Receptors Human genes 0.000 abstract 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 abstract 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
Un anticuerpo monoclonal aislado o porción del mismo de unión al antígeno, que se une a un epítopo sobre el receptor de tipo Toll 2 humano con una KD de 3x10-8 M o menor y que media el antagonismo TLR2 independientemente de la unión del anticuerpo, o de porción del mismo de unión al antígeno, a CD32 (receptor II Fc gamma), en donde el epítopo es reconocido por un anticuerpo de referencia, en donde el anticuerpo de referencia comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos de SEQ ID NO:4 y una región variable de cadena ligera que comprende la secuencia de aminoácidos de SEQ ID NO:1.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27023909P | 2009-07-06 | 2009-07-06 | |
| IE20090514 | 2009-07-06 | ||
| IE20090514A IE20090514A1 (en) | 2009-07-06 | 2009-07-06 | Humanised antibodies and uses therof |
| US270239P | 2009-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2658224T3 true ES2658224T3 (es) | 2018-03-08 |
Family
ID=43428820
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14158199.1T Active ES2658224T3 (es) | 2009-07-06 | 2010-07-06 | Anticuerpos humanizados contra receptores de tipo Toll 2 y sus usos |
| ES10728262.6T Active ES2488615T3 (es) | 2009-07-06 | 2010-07-06 | Anticuerpos humanizados contra receptores de tipo Toll 2 y sus usos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10728262.6T Active ES2488615T3 (es) | 2009-07-06 | 2010-07-06 | Anticuerpos humanizados contra receptores de tipo Toll 2 y sus usos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8734794B2 (es) |
| EP (2) | EP2451842B1 (es) |
| JP (2) | JP5847707B2 (es) |
| KR (1) | KR101572171B1 (es) |
| CN (1) | CN102482356B (es) |
| AU (1) | AU2010270241B2 (es) |
| BR (1) | BRPI1014016B8 (es) |
| CA (1) | CA2766996C (es) |
| ES (2) | ES2658224T3 (es) |
| IE (1) | IE20090514A1 (es) |
| IL (1) | IL217225A (es) |
| IN (1) | IN2012DN00938A (es) |
| MX (1) | MX2012000316A (es) |
| NZ (2) | NZ615441A (es) |
| RU (1) | RU2563344C2 (es) |
| WO (1) | WO2011003925A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201205633D0 (en) * | 2012-03-30 | 2012-05-16 | Opsona Therapeutics Ltd | Toll-like receptor 2 binding epitope and binding members thereto |
| US10047164B2 (en) | 2012-10-19 | 2018-08-14 | Opsona Therapeutics Limited | Methods and compositions for the treatment of pancreatic cancer |
| EP2722342A1 (en) | 2012-10-19 | 2014-04-23 | Opsona Therapeutics Limited | Methods and compositions for the treatment of pancreatic cancer |
| KR101478426B1 (ko) | 2013-02-08 | 2014-12-31 | 아주대학교산학협력단 | 톨 유사 수용체 2를 포함하는 백질 뇌졸중 검출용 바이오마커 및 톨 유사 수용체 2의 의학적 용도 |
| EP3560960A1 (en) * | 2013-04-22 | 2019-10-30 | The University of Tokyo | Preventive or therapeutic agent for inflammatory disease |
| CN103319600B (zh) * | 2013-06-19 | 2014-12-17 | 南京军区军事医学研究所 | 一种人源抗TLR4抗体Fab及其制备方法与应用 |
| TR201901045T4 (tr) | 2014-02-28 | 2019-02-21 | Astellas Pharma Inc | İnsan TLR2 ve insan TLR4'e bağlanan yeni bispesifik antikor. |
| CN104403001B (zh) * | 2014-12-12 | 2018-01-16 | 中国人民解放军南京军区军事医学研究所 | 一种全人源抗TLR4的抗体Fab及其全分子抗体IgG和应用 |
| KR20170105558A (ko) | 2015-01-30 | 2017-09-19 | 각코우호우징 사이타마이카다이가쿠 | 항 alk2 항체 |
| FR3048971A1 (fr) * | 2016-03-15 | 2017-09-22 | Univ Rabelais Francois | Constructions peptidiques bispecifiques et leur utilisation dans le traitement de maladies notamment imflammatoires |
| US20210009707A1 (en) * | 2016-12-02 | 2021-01-14 | Neuramedy Co., Ltd. | Methods and Compositions for the Treatment of Myelodysplastic Syndrome |
| WO2018115973A2 (en) * | 2016-12-22 | 2018-06-28 | Avectas Limited | Vector-free intracellular delivery by reversible permeabilisation |
| WO2018185284A1 (en) | 2017-04-07 | 2018-10-11 | Miltenyi Biotec Gmbh | POLYPEPTIDES WITH MUTANT HUMAN IgG4 |
| CA3089709A1 (en) * | 2018-01-29 | 2019-08-01 | The Regents Of The University Of California | Therapies and methods to treat tlr2-mediated diseases and disorders |
| EP3583949A1 (en) | 2018-06-19 | 2019-12-25 | Opsona Therapeutics Limited | Toll-like receptor 2 (tlr2) antagonists for the treatment of ovarian cancer |
| KR20200050715A (ko) * | 2018-11-02 | 2020-05-12 | 주식회사 젠센 | Tlr 억제 펩타이드를 포함하는 루푸스 예방 또는 치료용 조성물 |
| CN111109198B (zh) * | 2019-03-29 | 2021-08-20 | 成都华西海圻医药科技有限公司 | 一种葡萄膜炎动物模型构建方法 |
| CN111393530A (zh) * | 2020-03-30 | 2020-07-10 | 中国人民解放军南部战区总医院 | 新人源tlr2胞外区段单克隆抗体及其制备方法和应用 |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9927332D0 (en) * | 1999-11-18 | 2000-01-12 | Leiv Eiriksson Nyfotek As | Novel antibody and uses thereof |
| AU2002218166A1 (en) | 2000-09-08 | 2002-03-22 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| CN1809357B (zh) * | 2003-06-20 | 2010-12-22 | 科勒制药有限公司 | 小分子Toll样受体(TLR)拮抗剂 |
| US7388080B2 (en) | 2003-08-20 | 2008-06-17 | University Of Massachusetts | Selective inhibition of toll-like receptor-2 |
| WO2005028509A1 (en) * | 2003-09-23 | 2005-03-31 | Technische Universitaet Muenchen | Tlr2 antagonistic antibody and use thereof |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| SG158098A1 (en) * | 2004-11-30 | 2010-01-29 | Centocor Inc 22 30 74 Date Of | Toll like receptor 3 antagonists, methods and uses |
| US20080206239A1 (en) | 2005-02-03 | 2008-08-28 | Antitope Limited | Human Antibodies And Proteins |
| US20070191272A1 (en) | 2005-09-27 | 2007-08-16 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| EP1989544B1 (en) | 2006-03-02 | 2011-06-22 | Antitope Limited | T cell assays |
| EP2173381B1 (en) * | 2007-05-14 | 2013-10-02 | NovImmune SA | Fc receptor-binding polypeptides with modified effector functions |
| JP5576275B2 (ja) * | 2007-08-03 | 2014-08-20 | オプソナ セラピューティクス リミテッド | 再灌流障害および組織損傷を処置するためのｔｌｒ−２拮抗薬の使用 |
-
2009
- 2009-07-06 IE IE20090514A patent/IE20090514A1/en not_active IP Right Cessation
-
2010
- 2010-07-06 EP EP10728262.6A patent/EP2451842B1/en active Active
- 2010-07-06 AU AU2010270241A patent/AU2010270241B2/en active Active
- 2010-07-06 RU RU2011153932/10A patent/RU2563344C2/ru active
- 2010-07-06 EP EP14158199.1A patent/EP2805973B1/en active Active
- 2010-07-06 WO PCT/EP2010/059677 patent/WO2011003925A1/en active Application Filing
- 2010-07-06 CN CN201080035690.4A patent/CN102482356B/zh active Active
- 2010-07-06 NZ NZ615441A patent/NZ615441A/en unknown
- 2010-07-06 KR KR1020127003134A patent/KR101572171B1/ko active IP Right Grant
- 2010-07-06 ES ES14158199.1T patent/ES2658224T3/es active Active
- 2010-07-06 NZ NZ597447A patent/NZ597447A/en unknown
- 2010-07-06 CA CA2766996A patent/CA2766996C/en active Active
- 2010-07-06 JP JP2012518974A patent/JP5847707B2/ja active Active
- 2010-07-06 MX MX2012000316A patent/MX2012000316A/es active IP Right Grant
- 2010-07-06 IN IN938DEN2012 patent/IN2012DN00938A/en unknown
- 2010-07-06 ES ES10728262.6T patent/ES2488615T3/es active Active
- 2010-07-06 BR BRPI1014016A patent/BRPI1014016B8/pt active IP Right Grant
- 2010-07-06 US US13/382,044 patent/US8734794B2/en active Active
-
2011
- 2011-12-27 IL IL217225A patent/IL217225A/en active IP Right Grant
-
2015
- 2015-08-28 JP JP2015169427A patent/JP6677466B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI1014016B1 (pt) | 2020-04-07 |
| CN102482356A (zh) | 2012-05-30 |
| IE20090514A1 (en) | 2011-02-16 |
| IN2012DN00938A (es) | 2015-04-03 |
| WO2011003925A1 (en) | 2011-01-13 |
| JP2012531922A (ja) | 2012-12-13 |
| US20120164159A1 (en) | 2012-06-28 |
| CN102482356B (zh) | 2016-05-25 |
| JP5847707B2 (ja) | 2016-01-27 |
| CA2766996A1 (en) | 2011-01-13 |
| IL217225A0 (en) | 2012-02-29 |
| NZ597447A (en) | 2013-12-20 |
| AU2010270241B2 (en) | 2015-02-19 |
| ES2488615T3 (es) | 2014-08-28 |
| US8734794B2 (en) | 2014-05-27 |
| EP2451842A1 (en) | 2012-05-16 |
| BRPI1014016A2 (pt) | 2016-09-13 |
| JP6677466B2 (ja) | 2020-04-08 |
| JP2016025863A (ja) | 2016-02-12 |
| EP2805973A3 (en) | 2015-03-04 |
| RU2563344C2 (ru) | 2015-09-20 |
| BRPI1014016B8 (pt) | 2020-05-19 |
| AU2010270241A1 (en) | 2012-02-02 |
| KR101572171B1 (ko) | 2015-11-26 |
| MX2012000316A (es) | 2012-04-20 |
| KR20120075457A (ko) | 2012-07-06 |
| RU2011153932A (ru) | 2013-08-20 |
| EP2805973A2 (en) | 2014-11-26 |
| EP2451842B1 (en) | 2014-05-14 |
| CA2766996C (en) | 2017-08-01 |
| IL217225A (en) | 2017-08-31 |
| NZ615441A (en) | 2014-10-31 |
| EP2805973B1 (en) | 2017-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2658224T3 (es) | Anticuerpos humanizados contra receptores de tipo Toll 2 y sus usos | |
| PE20120427A1 (es) | Anticuerpos contra el receptor de cgrp humano | |
| PE20091024A1 (es) | Anticuerpos monoclonales que se unen a anexelekto y sus usos | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| AR076564A1 (es) | Anticuerpos humanizados de axl(receptor de tirosina quinasa) | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| CR11691A (es) | Anticuerpos monoclonales contra la proteína rgm a y sus usos | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| BRPI0811526A2 (pt) | uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa | |
| CO6251325A2 (es) | Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) | |
| CL2014001074A1 (es) | Anticuerpos monoclonales que es anti proteina de union a adn de tar de 43 kda (tdp-43); polinucleotido que lo codifica; composicion farmaceutica que lo contiene; uso del anticuerpo. | |
| AR074563A1 (es) | Anticuerpos anti ligando 1 de muerte programada (anti-pd-l1) y su uso para mejorar la funcion de las celulas t | |
| CL2012000254A1 (es) | Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión. | |
| PE20180042A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| GT200900043A (es) | Anticuerpos monoclonales humanos especificos para light humano antagonistas | |
| CL2012003283A1 (es) | Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8. | |
| CO6251371A2 (es) | Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino | |
| ES2722300T3 (es) | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso | |
| PE20150222A1 (es) | Anticuerpos multiespecificos | |
| PE20080035A1 (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina | |
| ES2683847T3 (es) | Inmunoglobulina citotóxica | |
| PE20080846A1 (es) | Composiciones y metodos relacionados con los anticuerpos receptores de glucagon | |
| CR11030A (es) | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion |